$RNAC
Cartesian Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000119312523276086 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $8.266M $6.551M
YoY Change -50.78% -68.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.07M $6.614M
YoY Change 248.94% 14.63%
% of Gross Profit
Research & Development $21.83M $13.00M
YoY Change 15.1% -21.39%
% of Gross Profit
Depreciation & Amortization $272.0K $100.0K
YoY Change 12.86% -50.0%
% of Gross Profit
Operating Expenses $43.90M $19.62M
YoY Change 73.57% -12.07%
Operating Profit -$13.07M
YoY Change 717.07%
Interest Expense -$148.7M $1.273M
YoY Change -39955.5% 58.73%
% of Operating Profit
Other Income/Expense, Net -$11.67M $253.0K
YoY Change -184.97% 25200.0%
Pretax Income -$196.7M -$9.002M
YoY Change -3608.62% 9.59%
Income Tax -$19.00M $0.00
% Of Pretax Income
Net Earnings -$177.7M -$9.002M
YoY Change -3114.73% 14.05%
Net Earnings / Revenue -2149.26% -137.41%
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$1.12 -$0.06
COMMON SHARES
Basic Shares Outstanding 155.2M 153.4M
Diluted Shares Outstanding 154.8M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.91M $79.60M
YoY Change -42.86% -45.64%
Cash & Equivalents $76.91M $79.60M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $4.967M $3.493M
YoY Change 31.47% -44.64%
Inventory
Prepaid Expenses
Receivables $5.870M $4.898M
Other Receivables $2.981M $1.875M
Total Short-Term Assets $90.73M $89.87M
YoY Change -38.75% -43.72%
LONG-TERM ASSETS
Property, Plant & Equipment $2.113M $2.421M
YoY Change -24.37% -16.63%
Goodwill $48.16M
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.000M $2.000M
YoY Change 0.0% 0.0%
Other Assets $1.377M $1.405M
YoY Change 2.99% -13.7%
Total Long-Term Assets $214.3M $16.17M
YoY Change 1107.58% -13.04%
TOTAL ASSETS
Total Short-Term Assets $90.73M $89.87M
Total Long-Term Assets $214.3M $16.17M
Total Assets $305.1M $106.0M
YoY Change 83.89% -40.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.150M $375.0K
YoY Change 896.84% 75.23%
Accrued Expenses $14.73M $13.64M
YoY Change 4.61% 11.2%
Deferred Revenue $2.311M $4.140M
YoY Change 289.71% 8.38%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $68.21M $19.94M
YoY Change 172.0% -15.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $360.6M $25.77M
YoY Change 1135.2% -47.86%
Total Long-Term Liabilities $360.6M $25.77M
YoY Change 667.58% -63.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $68.21M $19.94M
Total Long-Term Liabilities $360.6M $25.77M
Total Liabilities $444.7M $45.71M
YoY Change 517.11% -51.04%
SHAREHOLDERS EQUITY
Retained Earnings -$614.6M -$437.0M
YoY Change 55.63% 9.02%
Common Stock $16.00K $15.00K
YoY Change 6.67% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$440.2M $60.33M
YoY Change
Total Liabilities & Shareholders Equity $305.1M $106.0M
YoY Change 83.89% -40.52%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$177.7M -$9.002M
YoY Change -3114.73% 14.05%
Depreciation, Depletion And Amortization $272.0K $100.0K
YoY Change 12.86% -50.0%
Cash From Operating Activities -$23.29M -$9.215M
YoY Change 96.52% -311.69%
INVESTING ACTIVITIES
Capital Expenditures $64.00K $0.00
YoY Change -69.67% -100.0%
Acquisitions
YoY Change
Other Investing Activities $6.561M $0.00
YoY Change 15.11% -100.0%
Cash From Investing Activities $6.497M $0.00
YoY Change 18.36% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.08M -24.79M
YoY Change -4150.49%
NET CHANGE
Cash From Operating Activities -23.29M -9.215M
Cash From Investing Activities 6.497M 0.000
Cash From Financing Activities 14.08M -24.79M
Net Change In Cash -2.708M -34.00M
YoY Change -57.42% 36.17%
FREE CASH FLOW
Cash From Operating Activities -$23.29M -$9.215M
Capital Expenditures $64.00K $0.00
Free Cash Flow -$23.35M -$9.215M
YoY Change 93.62% -292.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001453687
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37798
dei Entity Registrant Name
EntityRegistrantName
Cartesian Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1622110
dei Entity Address Address Line1
EntityAddressAddressLine1
65 Grove Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
923-1400
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SELB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
155204182
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79603000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106438000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
28164000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4898000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6596000
CY2023Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1875000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3162000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3493000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3778000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
89869000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
148138000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2421000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2794000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10339000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11617000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1377000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1311000
CY2023Q3 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
2000000
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
2000000
CY2023Q3 us-gaap Other Assets
OtherAssets
28000
CY2022Q4 us-gaap Other Assets
OtherAssets
26000
CY2023Q3 us-gaap Assets
Assets
106034000
CY2022Q4 us-gaap Assets
Assets
165886000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
375000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
316000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13637000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14084000
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
0
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
8476000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1787000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1608000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4140000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
593000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19939000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25077000
CY2023Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
0
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
17786000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8694000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10055000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3981000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
13091000
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
19140000
CY2023Q3 us-gaap Liabilities
Liabilities
45705000
CY2022Q4 us-gaap Liabilities
Liabilities
72058000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154854032
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154854032
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153042435
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
153042435
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
15000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
501919000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
493308000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436989000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-394937000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4616000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4558000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
60329000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
93828000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106034000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165886000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6551000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20710000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17738000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
93982000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13002000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16539000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49408000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53410000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6614000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5770000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18414000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17538000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
19616000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
22309000
us-gaap Operating Expenses
OperatingExpenses
67822000
us-gaap Operating Expenses
OperatingExpenses
70948000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13065000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1599000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50084000
us-gaap Operating Income Loss
OperatingIncomeLoss
23034000
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1299000
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
710000
us-gaap Investment Income Net
InvestmentIncomeNet
4024000
us-gaap Investment Income Net
InvestmentIncomeNet
932000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-61000
CY2023Q3 us-gaap Interest Expense
InterestExpense
1273000
CY2022Q3 us-gaap Interest Expense
InterestExpense
802000
us-gaap Interest Expense
InterestExpense
2833000
us-gaap Interest Expense
InterestExpense
2224000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3787000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6539000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6049000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7329000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
253000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
753000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
155000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9002000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8214000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42052000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
29165000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-321000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-321000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9002000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7893000
us-gaap Net Income Loss
NetIncomeLoss
-42052000
us-gaap Net Income Loss
NetIncomeLoss
29486000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-69000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
65000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9022000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7943000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42110000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
29522000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154804503
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152849992
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153870912
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
141969449
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154804503
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152849992
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153870912
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143792060
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
93828000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
149000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2276000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21663000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74579000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2283000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11387000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
65448000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
82000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2023Q3 selb Stock Issued During The Period Values Common Stock License Agreement
StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement
1500000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2321000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-20000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9002000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
60329000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22521000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
127000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1675000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-79000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2753000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-32000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
28778000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
55764000
CY2022Q2 selb Stock Issued During The Period Shares Common Stock And Warrants
StockIssuedDuringThePeriodSharesCommonStockAndWarrants
27428572
CY2022Q2 selb Stock Issued During The Period Values Common Stock And Warrants
StockIssuedDuringThePeriodValuesCommonStockAndWarrants
21480000
CY2022Q2 selb Stock Issued During The Period Shares Common Stock License Agreement
StockIssuedDuringThePeriodSharesCommonStockLicenseAgreement
892857
CY2022Q2 selb Stock Issued During The Period Values Common Stock License Agreement
StockIssuedDuringThePeriodValuesCommonStockLicenseAgreement
1000000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
79000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2564000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
118000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
8601000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
89606000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
62000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
446000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2601000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7893000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
84907000
us-gaap Net Income Loss
NetIncomeLoss
-42052000
us-gaap Net Income Loss
NetIncomeLoss
29486000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
571000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
1046000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
79000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
128000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1278000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
930000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
147000
us-gaap Share Based Compensation
ShareBasedCompensation
8380000
us-gaap Share Based Compensation
ShareBasedCompensation
8918000
us-gaap Paid In Kind Interest
PaidInKindInterest
455000
us-gaap Paid In Kind Interest
PaidInKindInterest
777000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6049000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7329000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-740000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1698000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2989000
selb Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current
IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent
-1287000
selb Increase Decrease In Contract With Customer Asset Allowance For Credit Loss Current
IncreaseDecreaseInContractWithCustomerAssetAllowanceForCreditLossCurrent
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
304000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
36000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-10000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-601000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7528000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-56044000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1638000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
635000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27875000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19782000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
28254000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
14000000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
33501000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
142000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
990000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28112000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20491000
us-gaap Repayments Of Debt
RepaymentsOfDebt
27457000
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
110000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
36859000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
156000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
231000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
189000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-27226000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
39215000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-69000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27058000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-993000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108038000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115436000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80980000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114443000
us-gaap Interest Paid Net
InterestPaidNet
1853000
us-gaap Interest Paid Net
InterestPaidNet
1616000
selb Issuance Of Common Stock License Agreement In Stock Based Compensation Expense
IssuanceOfCommonStockLicenseAgreementInStockBasedCompensationExpense
1500000
selb Issuance Of Common Stock License Agreement In Stock Based Compensation Expense
IssuanceOfCommonStockLicenseAgreementInStockBasedCompensationExpense
1000000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
65000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
145000
CY2023Q3 selb Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale
81000000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1400000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
22157000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154804503
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
28175000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
28164000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9002000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7893000
us-gaap Net Income Loss
NetIncomeLoss
-42052000
us-gaap Net Income Loss
NetIncomeLoss
29486000
CY2023Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
CY2022Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
7329000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9002000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9002000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7893000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7893000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42052000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-42052000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
22157000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152849992
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
153870912
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
141969449
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1822611
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154804503
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152849992
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153870912
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143792060
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53262355
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47375471
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
53262355
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17174322
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79603000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112843000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1377000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1600000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80980000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114443000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14084000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8164000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7999000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5743000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5205000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2421000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2794000
CY2023Q3 us-gaap Depreciation
Depreciation
100000
CY2022Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
500000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4774000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4242000
CY2023Q3 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
561000
CY2022Q4 selb Accrued Patent Fees Current
AccruedPatentFeesCurrent
696000
CY2023Q3 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5655000
CY2022Q4 selb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
7274000
CY2023Q3 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
2287000
CY2022Q4 selb Accrued Audit Fees Current
AccruedAuditFeesCurrent
985000
CY2023Q3 selb Accrued Interest Current
AccruedInterestCurrent
0
CY2022Q4 selb Accrued Interest Current
AccruedInterestCurrent
222000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
360000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
665000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13637000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
696000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
569000
us-gaap Operating Lease Cost
OperatingLeaseCost
2088000
us-gaap Operating Lease Cost
OperatingLeaseCost
1580000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
271000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
205000
us-gaap Variable Lease Cost
VariableLeaseCost
683000
us-gaap Variable Lease Cost
VariableLeaseCost
630000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
250000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
0
us-gaap Sublease Income
SubleaseIncome
756000
us-gaap Sublease Income
SubleaseIncome
0
CY2023Q3 us-gaap Lease Cost
LeaseCost
718000
CY2022Q3 us-gaap Lease Cost
LeaseCost
777000
us-gaap Lease Cost
LeaseCost
2021000
us-gaap Lease Cost
LeaseCost
2218000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
677000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2740000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2818000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2902000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2990000
CY2023Q3 selb Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
946000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13073000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2592000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10481000
us-gaap Operating Lease Payments
OperatingLeasePayments
1991000
us-gaap Operating Lease Payments
OperatingLeasePayments
1395000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y7M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.097
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
31228279
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.53
selb Stock Issued During Period Shares Warrants Canceled
StockIssuedDuringPeriodSharesWarrantsCanceled
-3576
selb Stock Issued During Warranted Canceled Price Per Share
StockIssuedDuringWarrantedCanceledPricePerShare
16.77
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
31224703
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.53
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
61737312
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2321000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2601000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8380000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8918000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8100000
CY2022Q4 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
593000
selb Contractwith Customer Liability Deferred Revenue Increase From Cash Receipts
ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts
10500000
selb Contractwith Customer Liability Deferred Revenue Revenue Recognized
ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized
-2972000
CY2023Q3 selb Contractwith Customer Liability Deferred Revenue
ContractwithCustomerLiabilityDeferredRevenue
8121000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
593000
selb Contractwith Customer Liability Increase From Cash Receipts
ContractwithCustomerLiabilityIncreaseFromCashReceipts
10500000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-2972000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8121000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
62400000
CY2022 selb Net Operating Losses Percentage Eligible To Be Carried Forward
NetOperatingLossesPercentageEligibleToBeCarriedForward
0.80
CY2022 selb Research Tax Credits Amount Eligible To Be Carried Forward
ResearchTaxCreditsAmountEligibleToBeCarriedForward
0.75
selb Defined Contribution Plan Employers Matching Contribution Vesting Period
DefinedContributionPlanEmployersMatchingContributionVestingPeriod
P2Y
CY2023Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
selb-20230930_cal.xml Edgar Link unprocessable
0001193125-23-276086-index-headers.html Edgar Link pending
0001193125-23-276086-index.html Edgar Link pending
0001193125-23-276086.txt Edgar Link pending
0001193125-23-276086-xbrl.zip Edgar Link pending
d549858d10q.htm Edgar Link pending
d549858dex311.htm Edgar Link pending
d549858dex312.htm Edgar Link pending
d549858dex32.htm Edgar Link pending
d549858dex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
selb-20230930.xsd Edgar Link pending
Show.js Edgar Link pending
selb-20230930_def.xml Edgar Link unprocessable
selb-20230930_lab.xml Edgar Link unprocessable
selb-20230930_pre.xml Edgar Link unprocessable
d549858d10q_htm.xml Edgar Link completed